Exploiting innate immunity for cancer immunotherapy DOI Creative Commons
Ming Yi, Tianye Li,

Mengke Niu

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Nov. 27, 2023

Abstract Immunotherapies have revolutionized the treatment paradigms of various types cancers. However, most these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosuppressive signaling with immune checkpoint blockade, or enhancing immunostimulatory bispecific T cell engager and chimeric antigen receptor (CAR)-T cell. Although agents already achieved great success, only a tiny percentage patients could benefit from immunotherapies. Actually, immunotherapy efficacy is determined multiple components in tumor microenvironment beyond immunity. Cells innate arm system, such as macrophages, dendritic cells, myeloid-derived suppressor neutrophils, natural killer unconventional also participate cancer evasion surveillance. Considering that cornerstone antitumor response, utilizing immunity provides potential therapeutic options for control. Up to now, exploiting agonists stimulator interferon genes, CAR-macrophage -natural therapies, metabolic regulators, novel exhibited potent activities preclinical clinical studies. Here, we summarize latest insights into roles cells discuss advances arm-targeted strategies.

Language: Английский

Innate Immunity and Cancer Pathophysiology DOI Open Access
Laura Maiorino, Juliane Daßler‐Plenker, Lijuan Sun

et al.

Annual Review of Pathology Mechanisms of Disease, Journal Year: 2021, Volume and Issue: 17(1), P. 425 - 457

Published: Nov. 18, 2021

Chronic inflammation increases the risk of several cancers, including gastric, colon, and hepatic cancers. Conversely, tumors, similar to tissue injury, trigger an inflammatory response coordinated by innate immune system. Cellular molecular mediators modulate tumor growth directly influencing adaptive response. Depending on balance cell types signals within microenvironment, can support or restrain tumor. Adding complexity, research from past two decades has revealed that cells are highly heterogeneous plastic, with variable phenotypes depending type, stage, treatment. The field is now cusp being able harness this wealth data (

Language: Английский

Citations

107
Dendritic cells as orchestrators of anticancer immunity and immunotherapy DOI
Ignacio Heras‐Murillo, Irene Adán‐Barrientos, Miguel Á. Galán

et al.

Nature Reviews Clinical Oncology, Journal Year: 2024, Volume and Issue: 21(4), P. 257 - 277

Published: Feb. 7, 2024

Language: Английский

Citations

105
Dendritic cells as shepherds of T cell immunity in cancer DOI Open Access
Mikaël J. Pittet, Mauro Di Pilato, Christopher Garris

et al.

Immunity, Journal Year: 2023, Volume and Issue: 56(10), P. 2218 - 2230

Published: Sept. 13, 2023

Language: Английский

Citations

92
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy DOI Creative Commons

Zaoqu Liu,

Zhaokai Zhou, Qin Dang

et al.

Theranostics, Journal Year: 2022, Volume and Issue: 12(14), P. 6273 - 6290

Published: Jan. 1, 2022

Chimeric antigen receptor (CAR)-T cell therapy represents a landmark advance in personalized cancer treatment.CAR-T strategy generally engineers T cells from specific patient with new antigen-specificity, which has achieved considerable success hematological malignancies, but scarce benefits solid tumors.Recent studies have demonstrated that tumor immune microenvironment (TIME) cast profound impact on the immunotherapeutic response.The immunosuppressive landscape of TIME is critical obstacle to effector activity CAR-T cells.Nevertheless, every cloud silver lining.The components also shed inspiration reshaping friendly by targeting them engineered CARs.Herein, we summarize recent advances disincentives and discuss approaches technologies enhance efficacy via addressing current hindrances.Simultaneously, firmly believe parsing TIME, rationally manipulating complex interactions components, optimizing for each patient, immunotherapy responsiveness malignancies will be substantially enhanced, novel therapeutic targets revealed.

Language: Английский

Citations

87
Exploiting innate immunity for cancer immunotherapy DOI Creative Commons
Ming Yi, Tianye Li,

Mengke Niu

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Nov. 27, 2023

Abstract Immunotherapies have revolutionized the treatment paradigms of various types cancers. However, most these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosuppressive signaling with immune checkpoint blockade, or enhancing immunostimulatory bispecific T cell engager and chimeric antigen receptor (CAR)-T cell. Although agents already achieved great success, only a tiny percentage patients could benefit from immunotherapies. Actually, immunotherapy efficacy is determined multiple components in tumor microenvironment beyond immunity. Cells innate arm system, such as macrophages, dendritic cells, myeloid-derived suppressor neutrophils, natural killer unconventional also participate cancer evasion surveillance. Considering that cornerstone antitumor response, utilizing immunity provides potential therapeutic options for control. Up to now, exploiting agonists stimulator interferon genes, CAR-macrophage -natural therapies, metabolic regulators, novel exhibited potent activities preclinical clinical studies. Here, we summarize latest insights into roles cells discuss advances arm-targeted strategies.

Language: Английский

Citations

84